Gimv NV Overview
Gimv is Belgium's oldest and largest listed private equity company, an evergreen, balance-sheet investor that has spent more than 45 years buying, building and selling European mid-market businesses. Unlike closed-end fund managers, it invests its own permanent capital, which lets it hold companies longer and, since 2025, take long-horizon "Anchor" positions in larger champions such as Cegeka and Azelis alongside reference shareholder WorxInvest. Its sector-specialist teams operate four platforms — Consumer, Healthcare, Smart Industries and Sustainable Cities — across home markets in the Benelux, France and DACH. Following a EUR 247 mio rights issue in early 2025, Gimv is executing an explicit plan to double its portfolio, raised its annual portfolio-return target to 17.5%, and exited new life-sciences venture investing in January 2026. The portfolio reached a record EUR 2.4 billion in June 2026, yet the shares continue to trade at a material discount to NAV.
What Gimv does
Gimv acquires majority or significant minority equity stakes in privately held (and, via Anchor, selectively listed) European companies, works with management to accelerate growth — typically through organic expansion, buy-and-build acquisitions, internationalisation, professionalisation and, increasingly, digital transformation — and realises value via trade sales, secondary buyouts or IPOs. It is a principal investor: nearly all investments are made directly from its own balance sheet rather than through third-party funds. Historically Gimv also managed co-investment funds (e.g. Gimv-XL, final close EUR 609 mio) and earned management fees; this is now marginal (management fees from managed funds were EUR 78k in H1 2025 on the IFRS cash flow statement).
Company's own description (latest disclosures)
Gimv describes itself as a European investment company listed on Euronext Brussels with over 45 years of private equity experience, managing around EUR 2.5 billion of assets across some 60 companies. It positions itself as a recognised market leader in four sector-focused platforms (Consumer, Healthcare, Smart Industries, Sustainable Cities) plus Gimv Anchor Investments, partnering with entrepreneurial, innovative businesses with strong growth potential and supporting their transformation into market leaders. Each platform operates with a local team across its home markets of Benelux, France and DACH. Its long-standing tagline is "Building Leading Companies"; since FY2025 it has added a "Combining Intelligence" theme — combining entrepreneurial and human expertise with AI-enabled capabilities (H1 FY2026 press release).
Business and revenue model
| Revenue/return driver | Description | H1 FY2026 (EUR mio, Investment basis) | FY2025 9m (EUR mio) |
|---|---|---|---|
| Unrealised gains | Fair-value uplift, mainly driven by EBITDA growth at portfolio companies valued on multiples | 183.3 | 155.8 |
| Realised gains | Capital gains on exits above prior carrying value | 15.5 | 52.7 |
| Interest income | Mainly capitalised interest on shareholder loans | Included in portfolio result | 22.8 |
| Dividend income | Portfolio dividends | 0.0 | Included |
| Portfolio result | Sum of the above | 198.8 | 231.4 |
| Management/director fees and other operating income | Fees charged to portfolio companies and other | 2.5 | not separately verified |
Gimv's model is therefore 100% "investment return" — there is no product, subscription or licensing revenue. Cash comes from exits, interest received and dividends; cash is consumed by new and follow-on investments, operating costs (personnel, long-term incentive plan payouts), interest on bonds, and shareholder dividends.
Value-chain position, customers and end-markets
Gimv sits at the capital-provider layer of the corporate value chain. Its "customers" are, in effect, (i) entrepreneurs, families and management teams seeking a growth partner, (ii) selling sponsors (e.g. Ambienta sold Groupe Cap Vert to Gimv in 2026), and (iii) ultimately the buyers of its exits (strategics such as CCL Industries, Ipsen, Impact Healthcare; other sponsors). Its own shareholders are its capital providers.
End-markets served (through portfolio companies): consumer brands and food (juvenile products, hearing protection, spices, food-safety software, e-learning); healthcare services and medtech (outpatient and home care, oncology centres, equine care, spinal implants, CDMOs); industrial technology (electronics/mechatronics, communication systems, sports-surface machinery); and sustainable-cities services (energy and water network contracting, technical installations, energy renovation, tree and vegetation management, temporary energy rental); plus IT services (Cegeka) and specialty chemical distribution (Azelis) via Anchor.
Independent characterisation
Analytically, Gimv is best understood as a permanent-capital, mid-market buyout and growth investor with a recent pivot toward larger, longer-hold "core-plus" positions. Three features differentiate it from European peers: (1) its sector-platform organisation (rather than generalist deal teams); (2) its Benelux/France/DACH regional focus with physical offices in Antwerp, The Hague, Paris and Munich; and (3) since 2024, the presence of an entrepreneurial reference shareholder (WorxInvest, controlled by the Dierckx family vehicle structure; Executive Chairman Filip Dierckx is Gimv's Chairman) that co-invests in Anchor and Infravest. The 2025 recapitalisation, the step-change in investment pace (EUR 466 mio in 9 months) and the January 2026 exit from new life-sciences venture investing mark a shift from a diversified "Flemish development company" heritage toward a scaled, return-target-driven European private equity compounder.
Strategy
Stated strategy (themes from FY2024-25 / FY2025 reporting and investor communications)
-
"Building Leading Companies" — long-standing mission: partner with entrepreneurial, innovative businesses and transform them into market leaders.
-
Accelerated growth — "double the portfolio" — ambition announced in late 2024 and funded by the February 2025 rights issue. By June 2026 the portfolio was EUR 2.4 bn (≈+50% vs. the capital-increase moment), and above EUR 2.5 bn including Cap Vert.
-
Higher return target — annual portfolio return target raised from 15% to at least 17.5%.
-
Longer investment horizon and Anchor — "anchoring" companies with strong long-term growth potential via Gimv Anchor (with WorxInvest), aiming for sustained compounding value. Anchor portfolio is reported to be "ahead of schedule".
-
More efficient capital structure — use of debt at Gimv level (bonds, RCF doubled to EUR 400 mio) so equity is fully invested.
-
Sector focus — concentrate on four platforms plus Anchor; discontinued new Life Sciences investments (January 2026) to focus capital on sectors benefiting from digital transition.
-
"Combining Intelligence" / digital transformation — AI-augmented human expertise to help portfolio companies accelerate digital transformation; new ExCo-level Chief Digital Transformation role (September 2026).
-
Sustainability as value creation — first platform-specific sustainability value-creation blueprint (H1 2026); company-specific decarbonisation support.
-
Dividend policy — not to lower the dividend except in exceptional circumstances, and to increase it whenever sustainably possible.
Initiative register (last 24 months)
| Date | Initiative | Type | Targets / detail |
|---|---|---|---|
| Nov 2024 | Accelerated growth strategy | Strategic plan | Double portfolio; 17.5% return target; leverage |
| 2,024 | Infravest | Vehicle/partnership | With Belfius (20%) and WorxInvest (40%) |
| Jan–Feb 2025 | EUR 247 mio rights issue | Capital | Net EUR 243 mio |
| Feb 2025 | Gimv Anchor Investments JV | New business line | 75% Gimv / 25% WorxInvest; Cegeka first holding |
| Mar 2025 | Head of Anchor appointed | Organisation | Bart Troubleyn |
| 2,025 | Calendar-year reporting | Governance/reporting | FY2025 shortened to 9 months |
| Jan 2026 | Exit new Life Sciences investing | Portfolio strategy | 11 companies (≈5% of portfolio) run off |
| Q1 2026 | RCF doubled to EUR 400 mio | Financing | Strengthens investment capacity |
| Apr 2026 | Azelis stake | Anchor investment | 5% → >6% |
| Jun 2026 | Cap Vert | Platform investment | Top-10 holding |
| H1 2026 | Sustainability value-creation blueprint | ESG | First platform-specific blueprint |
| Sep 2026 | Chief Digital Transformation role | Organisation | External international hire, name TBA |
| Ongoing | Gimv Climate Plan | ESG | 70% own Scope 1 & 2 reduction target; >50% achieved |
Medium-term targets / guidance
| Target | Value | Status |
|---|---|---|
| Annual portfolio return | ≥17.5% (long-term objective; previously 15%; earlier long-term objective shown as 12%) | 18.8% annualised in H1 FY2026 |
| Portfolio size | Double (from ≈EUR 1.6 bn at the capital increase) | EUR 2.4 bn (Jun 2026); >EUR 2.5 bn with Cap Vert |
| Dividend | Not lowered; increase when sustainable | EUR 2.60 annual rate maintained (EUR 1.95 for 9m) |
| Earnings/NAV guidance | Not provided (no explicit EPS or NAV guidance) | — |
Products & Services
For an investment company, the "product catalog" is (a) its investment offerings to entrepreneurs, and (b) the portfolio holdings. Each holding is listed with what is publicly verifiable. Entry stake sizes and valuations per company are not publicly disclosed unless stated.
Gimv's "offerings" (investment products)
| Offering | Description | Typical counterparty | Pricing/terms |
|---|---|---|---|
| Majority buyouts | Control acquisitions, often with management reinvestment, as platform for buy-and-build | Founders, families, selling sponsors | — |
| Significant minority growth equity | Minority stakes with governance rights to fund expansion | Entrepreneurial firms | — |
| Continuation / reinvestment | Re-investment alongside new owners or in combined entities (e.g. Bugaboo-Joolz, Liveo/Medi-Markt) | Existing holdings | — |
| Anchor investments | Long-term, larger-ticket stakes in European champions, private or listed, co-invested 75/25 with WorxInvest | Cegeka, Azelis | — |
| Venture capital (Life Sciences) | Discontinued for new deals since Jan 2026; follow-ons in existing companies only | Biotech/medtech | Not applicable |
Gimv Anchor Investments
| Holding | Country | Activity | Entry | Key facts |
|---|---|---|---|---|
| Cegeka | Belgium | Independent European ICT services provider | 2025 (Anchor); Gimv historically a shareholder | Revenue ≈EUR 1.3 bn in 2025 (stable); "year of transition" with restructuring of prior acquisitions; three new board members; new CEO Koen Deryckere (ex-CEO & President France & Benelux at a large IT services group, per AGM 2026 deck). Largest single Gimv holding category per FY2025 top-5 table |
| Azelis Group NV | Belgium (BEL 20) | Specialty chemicals and food ingredients distribution | 30 Apr 2026 | 5% at announcement, >6% by 30 June 2026; Gimv Anchor expects to be a top-five shareholder; led by Bart Troubleyn and Floris van Halder |
Anchor portfolio total: ≈EUR 375 mio, ≈15% of total Gimv portfolio (Gimv H1 2026 results day presentation), of which 75% is funded from Gimv's balance sheet. Note: this figure appears to be on a 100% basis or to include WorxInvest's share; Gimv's own Anchor line was EUR 277 mio at 30 June 2026.
Healthcare platform
| Holding | Country | Activity | Entry | Notes |
|---|---|---|---|---|
| Spineart | Switzerland | Medtech: implants and technologies for spine surgery | 2025 (as top-5 holding; long-standing investor) | CHF 25 mio capital increase (Sep 2025) with EGS Beteiligungen; ≈EUR 140 mio 2025E revenue, 16% average growth over 5 years; >360 employees; BAGUERA® C cervical disc received FDA approval for 1- and 2-level use (Aug 2026); Spinem Robotics partnership (EUR 10 mio, Apr 2024) |
| Liveo Gruppe (from Medi-Markt) | Germany | Incontinence care at home | 2025 (continuation investment) | Top-10 holding |
| Equine Care Group | Belgium | High-quality equine medical care: clinics, ambulatory care, reproduction, supplements, lab | 2,025 | Top-10 holding; CNP joined to accelerate global expansion (Nov 2025); bolt-ons in H1 2026 |
| Novicare | Netherlands | B2B specialised medical care services in elderly and disability care | 2025 (Aug) | — |
| ILC (iLC) | France | Leading private group of cancer treatment centres | 2,025 | Top-20 holding |
| BioConnection | Netherlands | CDMO for injectable (bio)pharmaceuticals | 2,022 | Top-20; manufacturing capacity expansion in H1 2026; 100% renewable electricity |
| Awelando Gruppe (attribution probable) | Germany | Outpatient care in assisted living facilities and day care | 2,025 | Named in Gimv portfolio filter; description matches FY2025 new-investment slide |
| MVZ Holding | Switzerland | Group of medical practices | — | Sold Aug 2026, no NAV impact |
| AlpenBlu Clinics (formerly Les Psy Réunis) | Switzerland | Outpatient mental healthcare | — | Sold to Impact Healthcare, 30 Jun 2026 |
| Other names in portfolio filter | — | Benedenti (dental group practices, BE), Equipe Zorgbedrijven (NL), Curana, Ambulantis, Excellent Clinics, SGH Medical Pharma, rehaneo | — | Some may be exited |
Consumer platform
| Holding | Country | Activity | Entry | Notes |
|---|---|---|---|---|
| Alpine (attribution probable) | Netherlands | Passive consumer hearing protection | 2,025 | Top-5 holding in FY2025 table ("perfect sound, carefree enjoyment") |
| Bugaboo Group (Bugaboo-Joolz) | Netherlands | Premium strollers and adjacent juvenile products | 2025 reinvestment (Joolz held since 2016) | Gimv sold Joolz into the combination and reinvested (Jul 2025); top-20 |
| The Spice Factory | Belgium | Leading Belgian herbs and spices manufacturer | 2025 (FY2024-25) | Top-15; sustainability roadmap |
| Quality Guard | Belgium | Food safety compliance software/solutions | Nov 2025 | Platform for European buy-and-build; acquisitions in H1 2026 |
| sofatutor | Germany | Online learning platform | 2,021 | Top-15; acquired SchoolMouv (Q1 2026) |
| Other names in portfolio filter | — | Babyshop Group, Blendwell Food Group, The Wallfashion House (acquired control of Rasch, Apr 2024), Legallais (FR ironmongery distribution), United Dutch Breweries, Olyn, Wolf Lingerie, Hecht | — | — |
Smart Industries platform
| Holding | Country | Activity | Entry | Notes |
|---|---|---|---|---|
| Televic | Belgium | High-tech, high-quality communication systems | 2,020 | Top-5 holding; Televic Healthcare Solutions sold to Esprit ICT (Jul 2025) |
| Metis Group | Netherlands | Developer/manufacturer of electronic and mechatronic products and systems (formed by AME and Variass) | 2,022 | Top-10; A1 Electronics joined (Mar 2024); agreement to acquire majority of EPAC (Aug 2026) |
| SMG Sportplatzmaschinenbau | Germany | Machinery for installing and maintaining synthetic sports surfaces | 2,024 | Top-15 |
| German electrical engineering holding | Germany | End-to-end electrical engineering solutions | 2,021 | Top-15 |
| ALT Technologies | Netherlands | — | — | Majority stake sold to CCL Industries (Jan 2026) |
| Other names in portfolio filter | — | Projective Group, WDM-Deutenberg Group, Laser 2000, Kind Technologies, Köberl, Witec, RoboJob, Castelein Sealants, Arplas Systems, OTN Systems, Smart Battery Solutions | — | — |
Sustainable Cities platform
| Holding | Country | Activity | Entry | Notes |
|---|---|---|---|---|
| Groupe Cap Vert | France | France's leading multi-specialist tree and vegetation critical-management services | Signed 25 Jun 2026; closing expected Sep 2026 | ≈EUR 180 mio revenue; >1,200 staff; ≈60 branches; >18 acquisitions since Dec 2021 under Ambienta; to be a top-10 Gimv holding; CEO Eric Girot |
| Hemink | Netherlands | B2B energy-renovation and maintenance specialist for sustainable real estate | Jul 2025 | Top-20; bolt-ons in H1 2026 |
| Fronnt (attribution probable) | Belgium | One-stop shop for technical installations, products and services | 2,022 | Top-15; Intec group, Van Severen and Famil joined (Aug 2025) |
| Dutch network contractor | Netherlands | Specialist contractor in cable and pipeline networks for energy and water | 2,021 | Top-5 holding |
| French fencing group | France | Production of gates and fencing and fencing solutions | 2,022 | Top-10 |
| French temporary-energy rental group (Tibbloc, attribution probable) | France | Rental of ready-to-use temporary energy solutions | 2,024 | Top-10 |
| German pipeline/civil engineering group | Germany | Pipeline construction, cable laying, specialised civil engineering | 2,022 | Top-20 |
| Itineris | Belgium | Utilities software | 2,013 | Exited in FY2025 |
| Other names in portfolio filter | — | Itho Daalderop & Klimaatgarant (NL), Brakel (natural climate control/fire safety), Well Services Group, Acertys Group, Alro Group, E.GRUPPE, Techinfra, GPNZ, Coolworld Rentals | — | — |
Life Sciences (run-off: 10 companies at 30 June 2026)
| Holding | Activity | Latest verified milestone |
|---|---|---|
| Exciva (Germany) | Clinical management of neuropsychiatric symptoms in Alzheimer's disease | Gimv co-led EUR 51 mio Series B with EQT Life Sciences (Jan 2026) |
| Kinaset Therapeutics | Inhaled therapies for respiratory disease | USD 103 mio Series B (Jan 2026) |
| Mediar Therapeutics | First-in-class fibrosis portfolio | USD 76 mio Series B (Jan 2026) |
| Complement Therapeutics | CTx001 for geographic atrophy secondary to AMD | FDA IND clearance (Oct 2025); FDA Fast Track (Jan 2026) |
| Kivu Bioscience | KIVU-107 PTK7-targeting ADC | First patient dosed Phase 1 (Jan 2026) |
| ImmunOs Therapeutics | Immuno-oncology | New CEO (Jan 2026) |
| Topas Therapeutics | Immune tolerance; celiac disease | Phase 2 readout late 2024 |
| Biotalys (listed) | Protein-based biocontrol | US EPA approval for EVOCA (Dec 2025) |
| Onera Health | Sleep diagnostics | Gimv co-led EUR 30 mio Series C |
| ImCheck Therapeutics | Immuno-oncology | Exited: sold to Ipsen (Oct 2025) |
Infra & other
| Holding | Description |
|---|---|
| Infravest | Vehicle with Belfius (20%) and WorxInvest (40%); Gimv sold 50% of its stake to WorxInvest in FY2024-25. Holds stakes in listed TINC (Gimv participated in TINC's rights issue in FY2025) and unlisted DG Infra Yield. ≈4% of portfolio |
| 3F / other | Legacy fund-of-funds positions; ≈1% of portfolio at Dec 2025 |
Concentration
-
Five largest investments: EUR 635 mio, ≈30% of portfolio (Dec 2025).
-
Ten largest: EUR 1,016 mio at Dec 2025; 50.3% of total at June 2026.
-
Twenty largest: EUR 1,476 mio, ≈70% of portfolio (Dec 2025).
-
No single investment >10% of portfolio value (June 2026).
-
Vintage profile (Dec 2025): 38% invested 2024 or later; 34% 2021–2023; 14% 2018–2020; 13% 2016–2017; 1% 2015 or earlier — a young portfolio that implies exits are weighted to 2027+.
-
Valuation method (Dec 2025): multiples 60%; price of last round 37%; listed 1%; other 2%.
Financial Narrative
Source for annual figures: Gimv "Key financial information" (consolidated, IFRS), FY2023-24 and FY2024-25 results releases, FY2025 deck. FY2025 = 9 months.
Income statement analogue
Notes: (a) In this table FY2025A = FY2024-25 (12 months) and FY2025B = shortened FY2025 (9 months). (b) Diluted EPS is not separately disclosed; no material dilutive instruments were identified (LTIP is cash-settled). (c) Gross profit, operating income in an industrial sense, EBITDA and associated margins are N/M for an investment company. (d) A third-party profile (Beursgenoten) cites FY2024-25 "revenue" of EUR 300.2 mio, consistent with the implied portfolio result above. (e) FY2025 dividend of EUR 1.95 is the EUR 2.60 annual rate pro-rated for 9 months.
Net profit "margin" analogue (net profit / portfolio result): FY2022 ≈69%; FY2023 N/M; FY2024 ≈75%; FY2025A ≈73%; FY2025B ≈75%. The gap reflects operating costs, the LTIP (Gimv's carried-interest equivalent for staff), finance costs and minority interests.
Cost structure (H1 FY2026, Investment basis): services and other goods EUR 7.8 mio; remuneration EUR 14.9 mio; LTIP benefits EUR 12.1 mio; depreciation EUR 1.4 mio; other operating expenses EUR 4.8 mio — total ≈EUR 41 mio for six months, or ≈EUR 82 mio annualised, ≈3.9% of NAV annualised (including LTIP) or ≈3.3% excluding LTIP. Finance costs EUR 5.3 mio; finance income EUR 2.4 mio; tax EUR 0.9 mio.
Commentary: Gimv's earnings are volatile and multiple-driven at the extremes (FY2019-20 and FY2022-23 losses), but over the past three full periods have been driven chiefly by EBITDA growth at portfolio companies: in H1 FY2026 EBITDA growth alone contributed EUR 196.3 mio of the EUR 198.8 mio portfolio result, while multiples were stable at 9.7x. Gimv has beaten its return target in each of the last four reporting periods (19.1%, 19.3%, 19.1% annualised, 18.8% annualised), and in eight of the ten years to 2024 had exceeded its then 15% target (KBC Securities).
Interim trend (calendar-year basis)
H1 2025 is restated to January–June 2025. Note: Simply Wall St reports H1 2026 EPS of EUR 3.40 vs EUR 5.15 — this conflicts with the company's EUR 4.0 vs EUR 2.3 and appears to reflect a mismatched period mapping after the fiscal-year change; company figures are used.
Balance sheet
Notes: FY2025B cash of EUR 323.7 mio comprises EUR 173.2 mio cash and EUR 150.5 mio marketable securities (Investment basis). At 30 June 2026 bonds on balance sheet were EUR 275.0 mio non-current plus EUR 83.8 mio current (current includes the EUR 75 mio tranche repaid 5 July 2026, plus accrued items). Goodwill and intangibles are negligible (intangibles EUR 0.3 mio). Working capital is N/M; current assets EUR 137.0 mio vs current liabilities EUR 94.5 mio at 30 June 2026.
Leverage and liquidity at 30 June 2026:
Gimv states its equity is now "more than fully invested" in the portfolio — a deliberate move from a structurally net-cash position (EUR 668.8 mio liquidity at March 2025) to modest net debt, consistent with the November 2024 strategy to use leverage more efficiently.
Cash flow analogue
FY2025A divestments include the sale to WorxInvest of 25% of Gimv's Anchor (Cegeka) stake and 50% of its Infravest stake. Optional (scrip) dividends reduce cash outflow (e.g. 64.2% of FY2024-25 dividend rights taken in shares, EUR 41.8 mio reinvested). Capex is N/M (PP&E purchases EUR 0.2 mio in H1 2026). Buybacks: own-share purchases EUR 3.5 mio and sales EUR 2.6 mio in H1 2026 (linked to staff share-purchase plan; a buyback was completed 4 March 2025 for this purpose). Operating cash flow on Investment basis in H1 2026 was EUR -121.1 mio, because investments are classified within operating activities for an investment entity; free cash flow is therefore N/M.
Ratios
Notes: (a) Gimv's table shows "+19.0%" for 31 Dec 2025, but price EUR 44.65 vs NAV EUR 55.1 is a 19.0% discount; the sign appears to be a presentation error and is corrected here. (b) ROIC, net debt/EBITDA, interest coverage on EBITDA, asset turnover and cash conversion cycle are N/M. (c) Debt/equity at 30 June 2026 ≈ 0.17x (EUR 350 mio bonds / EUR 2,105 mio equity), falling to ≈0.13x after the July 2026 repayment. (d) Interest cover analogue: H1 2026 profit before financing EUR 162.8 mio vs finance costs EUR 5.3 mio ≈ 31x.
Growth metrics
Key analytical point: NAV per share has compounded far more slowly than the portfolio because (i) Gimv distributes roughly a third or more of profits as dividends, (ii) the February 2025 rights issue was priced at EUR 34.50 — about 35–38% below the prevailing NAV — mechanically diluting NAV/share (NAV/share was EUR 55.6 at Sep 2024 and EUR 53.3 at Mar 2025 "after the impact of the capital increase"), and (iii) LTIP and running costs absorb roughly 3–4% of NAV annually.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Content | Status |
|---|---|---|
Consumer (CO) | Consumer-facing brands, food, education, consumer services | Core platform |
Healthcare (HC) | Care services, medtech, healthcare products and services (renamed from "Health & Care") | Core platform |
Smart Industries (SI) | Industrial technology, electronics, automation, B2B tech services | Core platform; head departing (Sep 2026) |
Sustainable Cities (SC) | Infrastructure services, energy transition, utilities, building technology | Core platform |
Gimv Anchor Investments | Long-term (minority or significant) stakes in larger European champions; JV 75% Gimv / 25% WorxInvest | Core since Feb 2025 |
Life Sciences (LS) | Venture investments in pre-revenue, R&D-driven biotech/medtech | Run-off (no new investments since 26 Jan 2026) |
Infra & other (Infravest, 3F, other) | Infravest (with Belfius and WorxInvest) holding TINC and DG Infra Yield stakes; legacy fund-of-funds ("3F") | Non-core / financial |
Revenue by Segment (EUR)
| Segment (EUR mio) | Dec2025 | Jun2026 |
|---|---|---|
Consumer | 369 | 412 |
Healthcare | 503 | 504 |
Smart Industries | 454 | 507 |
Sustainable Cities | 418 | 480 |
Anchor | 165 | 277 |
Life Sciences | 109 | 112 |
Infra and other | 103 | 115 |
Total portfolio | 2,121 | 2,407 |
Segment share of portfolio (%)
| Segment share of portfolio (%) | Dec2025 | Jun2026 |
|---|---|---|
Consumer | 17 | 17 |
Healthcare | 24 | 21 |
Smart Industries | 21 | 21 |
Sustainable Cities | 20 | 20 |
Anchor | 8 | 12 |
Life Sciences | 5 | 5 |
Infra and other | 5 | 5 |
Segment Overview — Consumer
| Segment | Realised result (EUR mio) | Unrealised result (EUR mio) | Interest income (EUR mio) | Portfolio result (EUR mio) | Portfolio return (%) 9m |
|---|---|---|---|---|---|
Consumer | 4.3 | 1.5 | 7.7 | 13.6 | 4.8 |
Healthcare | 0.0 | 48.3 | 3.1 | 51.3 | 18.8 |
Life Sciences | 17.4 | -21.0 | 0.6 | -3.0 | -2.2 |
Smart Industries | -3.6 | 53.2 | 6.7 | 56.3 | 14.7 |
Sustainable Cities | 32.7 | 67.0 | 4.4 | 104.1 | 31.5 |
Anchor | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Infra & 3F | 1.9 | 6.7 | 0.4 | 9.1 | 16.8 |
Total | 52.7 | 155.8 | 22.8 | 231.4 | 14.3 |
Segment Margins & Growth (%)
| Metric (like-for-like, portfolio companies) | FY2025 (calendar 2025, latest estimates) | H1 2026 YTD vs prior year |
|---|---|---|
Sales growth, core platforms | ≈10–11% | 8% |
EBITDA growth, core platforms | ≈15% | 12% |
Share of growth that is organic | ≈2/3 (EBITDA) | ≈2/3 (sales and EBITDA) |
Platforms with EBITDA growth >20% | Healthcare, Sustainable Cities | — |
Weighted average EV/EBITDA used | 9.7x (after -17% calibration) | 9.7x (after -16% calibration) |
Average portfolio leverage (net senior financial debt/EBITDA) | 1.8x (48 companies) | — |
Companies with leverage >4x | 9 (<5% of portfolio value) | — |
“—” = not publicly disclosed.
Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
|---|---|---|---|---|---|
Period label | Apr21–Mar22 | Apr22–Mar23 | Apr23–Mar24 | Apr24–Mar25 | Apr25–Dec25 (9m) |
Metric | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
Portfolio result EUR mio (FY22–FY25A implied) | 251.5 | -1.4 | 290.9 | 300.9 | 231.4 |
Gross portfolio return % | 20.4 | -0.1 | 19.1 | 19.3 | 14.3 |
Net profit EUR mio | 174.3 | -59.5 | 217.1 | 219.0 | 173.3 |
Net return on equity % | 13.7 | -4.2 | 16.5 | 14.7 | 9.0 |
EPS EUR (basic) | 6.59 | -2.20 | 7.79 | 7.47 | 4.80 |
Gross dividend per share EUR | 2.60 | 2.60 | 2.60 | 2.60 | 1.95 |
Payout ratio % | 37.4 | — | 32.6 | 33.1 | 41.4 |
Total gross dividend EUR mio | 65.1 | 69.3 | 70.8 | 72.5 | 71.8 |
Financial Analysis
| Metric | H12025 | H12026 |
|---|---|---|
Portfolio result EUR mio | 119.6 | 198.8 |
Portfolio return % (non-annualised) | 6.7 | 9.4 |
Net result EUR mio | 85.8 | 148.4 |
Net return % (non-annualised) | 5.2 | 7.5 |
Net result per share EUR | 2.3 | 4.0 |
Investments EUR mio | 226.4 | 134.0 |
Exit proceeds EUR mio | 369.7 | 42.0 |
Balance Sheet (EUR) and Per-Share Data
| Metric (EUR mio, IFRS unless noted) | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B | H12026 |
|---|---|---|---|---|---|---|
Total assets | 1,840.6 | 1,728.5 | 1,917.2 | 2,365.0 | 2,456.4 | 2,541.3 |
Portfolio (Investment basis) | 1,448.5 | 1,522.9 | 1,559.0 | 1,623.3 | 2,120.9 | 2,407.3 |
Cash and equivalents (incl. marketable securities where noted) | 377.8 | 194.4 | 346.8 | 668.8 | 323.7 | 131.4 |
Equity (group share) | 1,413.0 | 1,312.4 | 1,489.3 | 1,906.8 | 2,029.5 | 2,105.1 |
NAV per share EUR | 53.0 | 48.2 | 53.4 | 53.3 | 55.1 | 57.2 |
Total liabilities (computed: assets − equity) | 427.6 | 416.1 | 427.9 | 458.3 | 426.9 | 436.2 |
Bonds outstanding, principal | — | — | — | — | 350 | 350 |
Shares outstanding mio | 26.65 | 27.22 | 27.87 | 35.77 | 36.81 | 36.81 |
Financial Analysis — Cash on balance sheet
| Item | EUR mio |
|---|---|
Cash on balance sheet | 131.4 |
Undrawn revolving credit facility (doubled in Q1 2026) | 400.0 |
Total available liquidity | 531.4 |
Bonds outstanding | 350.0 |
Net cash (company-reported) | -216.0 |
Bonds after 5 Jul 2026 repayment | 275.0 |
Available liquidity after repayment | 456.4 |
Long-term incentive plan (LTIP) liabilities | 57.7 |
Lease liabilities | 9.5 |
Dividends & Capital Returns (EUR)
| Metric (EUR mio) | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
|---|---|---|---|---|---|
Investments (own balance sheet) | 193.8 | 260.6 | 115.8 | 336.1 | 466.4 |
Divestments (own balance sheet) | 218.9 | 175.0 | 364.6 | 560.0 | 196.5 |
Net investment (investments − divestments) | -25.1 | 85.6 | -248.8 | -223.9 | 269.9 |
Gross dividend declared for the year | 65.1 | 69.3 | 70.8 | 72.5 | 71.8 |
Returns & Leverage Ratios (%) — ROE %
| Ratio | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
|---|---|---|---|---|---|
ROE % (reported net return on equity) | 13.7 | -4.2 | 16.5 | 14.7 | 9.0 |
ROA % (net profit / year-end total assets, calc.) | 9.5 | -3.4 | 11.3 | 9.3 | 7.1 |
Equity / total assets % (calc.) | 76.8 | 75.9 | 77.7 | 80.6 | 82.6 |
Premium (+) / discount (−) to NAV % (company-reported) | 3.0 | -7.7 | -16.7 | -26.1 | -19.0 |
Share price at FY close EUR | 54.60 | 44.50 | 44.50 | 39.40 | 44.65 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Portfolio CAGR, Mar 2021 (EUR 1,233 mio) → Jun 2026 (EUR 2,407 mio) | ≈13.5% p.a. | Company-reported |
Portfolio growth since early-2025 capital increase | ≈+50% | Company-reported |
Equity growth, Mar 2021 (EUR 1,274 mio) → Jun 2026 (EUR 2,105 mio) | ≈+65% | Calc. (boosted by EUR 243 mio net rights issue and scrip dividends) |
NAV/share, Mar 2021 (EUR 49.0) → Jun 2026 (EUR 57.2) | ≈+17%, plus ≈EUR 13.5 cumulative gross dividends | Calc. |
Implied portfolio-result CAGR | N/M (FY2023 negative base) | — |
Last verified close | EUR 44.45 (28 Aug 2026) | Investing.com |
52-week range | EUR 41.80 – 50.10 | Investing.com |
1-year price change (to Aug 2026) | ≈+5.9% | Investing.com |
3-year price change (31 Mar 2023 EUR 44.50 → EUR 44.45) | ≈0% (calc.) | Gimv; Investing.com |
5-year price change (31 Mar 2021 EUR 51.00 → EUR 44.45) | ≈−12.8% (calc.) | Gimv; Investing.com |
Dividends received over 5 years (FY2021-22 to FY2025, gross) | EUR 12.35 per share | Gimv |
All-time high / low | EUR 57.65 (21 Feb 2020) / EUR 14.30 (10 Oct 2002) | TradingView |
Average daily volume | ≈20,000 shares | Investing.com |
Liquidity providers | KBC Securities; Bank Degroof Petercam | Gimv |
Region Overview
| Region | Share of portfolio % | Implied value EUR mio (calc. on 2,121) |
|---|---|---|
Belgium | 32 | 679 |
DACH (Germany, Austria, Switzerland) | 27 | 573 |
Netherlands | 24 | 509 |
France | 14 | 297 |
Rest of world | 3 | 64 |
Region share of portfolio (%)
| Region share of portfolio (%) | Dec2025 |
|---|---|
Belgium | 32 |
DACH | 27 |
Netherlands | 24 |
France | 14 |
Rest of world | 3 |
Platform Details
| Platform | Belgium | Netherlands | France | DACH |
|---|---|---|---|---|
Anchor | Cegeka | — | — | — |
Healthcare | Equine Care Group | BioConnection, Novicare | ILC | Spineart (CH), Liveo (DE) |
Consumer | The Spice Factory, Quality Guard | Alpine, Bugaboo Group | — | sofatutor (DE) |
Smart Industries | Televic | Metis Group | — | SMG (DE), electrical engineering (DE) |
Sustainable Cities | Fronnt | Network contractor, Hemink | Fencing group, temporary energy rental; Cap Vert (2026) | Pipeline/civil engineering (DE) |
Capital Markets
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
|---|---|---|---|---|---|---|
Share price EUR (FY close) | 51.00 | 54.60 | 44.50 | 44.50 | 39.40 | 44.65 |
NAV per share EUR | 49.0 | 53.0 | 48.2 | 53.4 | 53.3 | 55.1 |
Premium/discount to NAV % | 4.1 | 3.0 | -7.7 | -16.7 | -26.1 | -19.0 |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
Price / NAV | ≈0.78x | EUR 44.45 / EUR 57.2 (Jun 2026) |
Discount to NAV | ≈22% | Calc. |
P/E (TTM) | ≈7.0x | EUR 44.45 / TTM EPS EUR 6.35 (Investing.com) |
Dividend yield | ≈5.8% on EUR 2.60 run-rate; company stated 5.2% annualised on 26 May 2026 close | Calc.; Gimv |
EV/EBITDA, EV/Sales | N/M (investment company) | — |
P/B | Same as P/NAV | — |
Capital Markets — Number of covering analysts
| Item | Value | Source |
|---|---|---|
Number of covering analysts | 6 | Simply Wall St; TradingView |
Average 12-month target | EUR 51.25 | Investing.com |
High / low target | EUR 56 / EUR 42 | Investing.com; TradingView |
Implied upside vs EUR 44.45 | ≈+15% | Calc. |
Named coverage | KBC Securities (Livio Luyten) — positive tone, previously "accumulate/buy" on resumption after the capital increase | Bolero |
Capital Markets (FY2017–FY2025B)
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025A | FY2025B |
|---|---|---|---|---|---|---|---|---|---|---|
Gross DPS EUR | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.60 | 2.60 | 2.60 | 2.60 | 1.95 |
Capital Markets — Moody's / S&P / Fitch
| Item | Detail |
|---|---|
Moody's / S&P / Fitch | No public credit rating identified — Gimv appears to be unrated |
Bonds | EUR 350 mio outstanding at 30 Jun 2026; EUR 75 mio tranche matured/repaid 5 Jul 2026; EUR 275 mio outstanding thereafter. |
Revolving credit facility | EUR 400 mio, undrawn at 30 Jun 2026; renegotiated and doubled with Belgian banks in Q1 2026; maturity not disclosed in reviewed sources |
Net cash | −EUR 216 mio at 30 Jun 2026 (company-reported) |
Analyst Conclusions
Management guidance and consensus
Gimv does not give earnings or NAV guidance. Its standing targets are a portfolio return of at least 17.5% per year, doubling the portfolio, and a non-declining dividend. Management expressed "strong confidence in continued above-market growth performance" based on portfolio companies' 2026 budgets (FY2025 deck), and in September 2026 reported that market multiples since 30 June had not indicated any need for valuation adjustment.
Bull case
-
Compounding at ≈15% NAV growth plus a ≈5–6% yield: H1 2026 NAV/share grew 7.5% (15% annualised) after paying a EUR 1.95 dividend; if sustained, the current ≈22% discount implies material upside even without a re-rating.
-
Deployment is largely done, liquidity remains: with the portfolio near EUR 2.5 bn including Cap Vert and EUR 456 mio of liquidity, Gimv can harvest growth from a young, recently-bought portfolio while retaining dry powder.
-
Identifiable catalysts: Spineart's FDA approval, Cegeka's new-CEO turnaround, Azelis' cyclical recovery, Cap Vert's buy-and-build and industrial recovery for Smart Industries.
Bear case
-
Structural discount: the discount widened from +3% (Mar 2022) to −26% (Mar 2025) despite record profits, suggesting the market applies a durable haircut for unlisted marks, costs/LTIP and a controlling shareholder.
-
Anchor concentration and minority positions: Cegeka's flat 2025 and Azelis' cyclicality put a large, growing share of NAV (≈12% Gimv share; ≈15% on a 100% basis) into big single names with limited control or exit flexibility.
-
Shift to net debt and back-ended exits: net cash turned to −EUR 216 mio, exits slowed to EUR 42 mio in H1 2026, and 38% of the portfolio is 2024+ vintage — a downturn could pressure marks before realisations validate them.
Key catalysts and monitorables (next 12 months)
| Item | Timing | What to watch |
|---|---|---|
| Cap Vert closing | Sep–Q4 2026 | Completion, entry multiple disclosure (if any), first bolt-ons |
| New Head of Smart Industries; CDTO introduction | H2 2026 | Team continuity |
| FY2026 annual results | 18 Feb 2027 | Full-year portfolio return vs 17.5%; NAV/share; exits; Anchor marks |
| FY2026 dividend proposal | Feb–May 2027 | Return to EUR 2.60 full-year rate or increase |
| Cegeka 2026 performance | 2026–27 | Revenue/margin recovery under new CEO |
| Spineart US commercial ramp | 2026–27 | Valuation uplift |
| Exit activity | Ongoing | Realisations at or above carrying value |
| WorxInvest stake | Ongoing | Further creeping increases; governance |
| Valuation multiples / calibration | Each reporting date | 9.7x average multiple; calibration factor |
| Energy prices / macro | Ongoing | Portfolio-company margins |
Concluding analyst verdict
Gimv enters late 2026 in the strongest operational shape of its recent history. The 2025 recapitalisation has been deployed quickly — EUR 466 mio in nine months, then Azelis and Cap Vert in 2026 — and the portfolio has grown to a record EUR 2.4 billion, above EUR 2.5 billion pro forma. More importantly, the quality of returns is high: H1 2026's EUR 199 mio portfolio result came almost entirely from EBITDA growth at portfolio companies, with multiples flat at 9.7x and look-through leverage a moderate 1.8x. Four consecutive reporting periods above the raised 17.5% target suggest the return ambition is credible rather than aspirational.
The equity story, however, has not kept pace. NAV per share has risen only modestly over five years once dividends and the dilutive EUR 34.50 rights issue are accounted for, and the shares still trade roughly 22% below the June NAV of EUR 57.2. The market appears to discount three things: the opacity of unlisted marks, the cost and LTIP drag (roughly 3–4% of NAV annually), and governance considerations around a 37% reference shareholder that is also a co-investor and buyer of Gimv assets. The Anchor strategy amplifies both upside and concentration; Cegeka's flat 2025 is a reminder that large holdings can stall.
The investment case hinges on Gimv converting a young portfolio into realised exits at or above book over 2027–2028, which would validate its marks and is the most plausible path to narrowing the discount. Key watch-points are exit pace, Anchor performance, team stability after the Smart Industries departure, and any further shift in WorxInvest's role.
All figures EUR; FY2025 is a 9-month period.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes | Prior roles / education | Birth year |
|---|---|---|---|---|
Koen Dejonckheere | CEO and executive director | CEO since Oct 2008 (one aggregator says 2015 — discrepancy) | MBA, M.Sc., engineering degree (Simply Wall St); joined Gimv 1998 per Altss | 1969 |
Kristof Vande Capelle | CFO (acting via a management company) | Long-standing CFO; co-signs management declarations | — | 1969 |
Edmond Bastijns | Chief Legal Officer & Secretary General | — | — | 1973 |
Bart Diels | Managing Partner & Head of Healthcare | — | — | 1969 |
Bart Troubleyn | Managing Partner & Head of Gimv Anchor | Since March 2025 | Former CEO/COO with international, M&A, restructuring and IT/digital transformation experience | — |
Tom Van de Voorde | Platform Head, Smart Industries | 19 years at Gimv; leaving (announced 3 Sep 2026); successor to be announced | — | — |
Erik Mampaey | — | Listed by Beursgenoten | — | — |
Koen Bouckaert | — | Listed by Beursgenoten | — | — |
Bram Vanparys | — | Listed by Beursgenoten | — | — |
New Chief Digital Transformation officer | Newly created ExCo role (Sep 2026) | Filled by "an external international profile"; name to be announced | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Notes |
|---|---|---|
Filip Dierckx | Chairman (since 21 May 2024); chair of remuneration committee | Executive Chairman of WorxInvest; non-independent |
Koen Dejonckheere | CEO, executive director | Non-independent |
Robert van Goethem | Director (co-opted May 2024 on WorxInvest recommendation) | Non-independent (shareholder representative) |
Marc Valentiny | Director (co-opted May 2024 on WorxInvest recommendation) | Non-independent (shareholder representative) |
Luc Missorten | Director | — |
Brigitte Boone | Director | Born 1960 |
Hilde Windels | Director | Born 1966 |
Johan Deschuyffeleer | Director | Born 1958 |
Manon Janssen | Director | Born 1961 |
Frank Verhaegen | Director | Born 1960 |
An Vermeersch | Director | Born 1971 |
Major Shareholders
| Holder | Shares | % of voting rights | Date / source |
|---|---|---|---|
WorxInvest NV | 13,672,016 | 37.14 | Current, Gimv shareholder structure page (after scrip dividends, rights issue and market purchases) |
WorxInvest NV — prior notifications | — | 28.73 → 32.32 → 35.44 | 21 May 2024 / 11 Feb 2025 / 30 Jul 2025 |
Norges Bank | — | 2.90 | Last notification 8 Jan 2018 (below 3% threshold; current holding not disclosed) |
Free float | 23,138,917 | 62.86 | Computed |
Competitive Landscape
Key Competitors
| Competitor | Type | Arena | Relative positioning vs Gimv |
|---|---|---|---|
Ackermans & van Haaren (BE, listed) | Diversified holding | Capital and some deals | Larger, more diversified (marine engineering, banking, real estate); long-hold model |
Sofina (BE, listed) | Family-controlled investment company | Capital | Larger; global growth/VC and fund exposure; trades at a discount |
GBL – Groupe Bruxelles Lambert (BE, listed) | Holding company | Capital; overlaps with Anchor-style listed stakes | Much larger; listed minority stakes plus private assets |
Deutsche Beteiligungs AG – DBAG (DE, listed) | Listed PE investor/manager | DACH mid-market deals; capital | Closest listed DACH analogue; fund-management fee income model |
Eurazeo (FR, listed) | Listed PE and asset manager | French mid-market deals; capital | Larger; third-party AUM model |
Wendel (FR, listed) | Investment holding | Capital | Larger; pivoting to asset management |
3i Group (UK, listed) | Listed PE | Capital (benchmark for listed PE) | Much larger; dominated by Action |
Mutares (DE, listed) | Special-situations PE | DACH/France deals | Turnaround focus vs Gimv's growth focus |
Waterland Private Equity (NL, private) | Buy-and-build PE | Benelux/DACH deals | Direct deal competitor in buy-and-build |
NPM Capital (NL, private) | Evergreen investor | Dutch deals | Permanent-capital competitor |
Bencis (BE/NL, private) | Mid-market PE | Benelux deals | Direct competitor; previously co-sold Xeikon with Gimv-XL |
Ambienta (IT, private) | Sustainability-focused PE | Sustainable Cities deals | Competitor and counterparty (sold Cap Vert to Gimv) |
IK Partners, Ardian, Naxicap, Sagard (private) | Pan-European / French mid-market PE | Deals | Larger fund-based competitors; Sagard bought Acceo from Gimv, Naxicap bought Accent Jobs |
Peer Comparison FY2025
| Metric | Gimv | DBAG | Eurazeo | Sofina |
|---|---|---|---|---|
Model | Balance-sheet direct PE, sector platforms | Balance sheet plus fund manager | Balance sheet plus large third-party AUM | Family holding, global growth/VC and funds |
NAV / equity | EUR 2,105 mio (Jun 2026) | — | — | — |
Recent annual portfolio return | 18.8% annualised (H1 2026) | — | — | — |
Discount to NAV | ≈22% (EUR 44.45 vs EUR 57.2) | — | — | — |
Dividend yield | ≈5.8% on EUR 2.60 run-rate | — | — | Low |
R&D intensity | N/M | N/M | N/M | N/M |



